Serious health threat of mucormycosis during the ongoing COVID-19 pandemic: what dermatologists need to know in this regard.
Аннотация
BACKGROUND
Recently, a surge of mucormycosis in patients affected with or recovered from SARS-Cov-2 has been noted, especially in developing countries such as India, Pakistan, and Iran.
AIM: To focus on existing data about the important aspects of COVID-associated mucormycosis.
METHODS
We searched on PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until August 28, 2021, for which we could access their full-texts, were included.
RESULTS
We found some recommendations made by ophthalmologists, anesthesiologists, and ENT surgeons and tried to summarize them to provide a practical guide for dermatologists.
CONCLUSION
Careful examination and clinical suspicion are the key factors for correct diagnosis especially in patients affected by or recently recovered from COVID. Implementing some preventive measures such as using a titrated dose of corticosteroids and encouraging patients to get vaccinated should be considered to tackling this serious issue.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.